PROTEASOMAL AND CALPAIN PROTEOLYSIS SYSTEMS IN DIFFERENT MOLECULAR SUBTYPES OF BREAST CANCER
https://doi.org/10.21294/1814-4861-2017-16-3-33-39
Abstract
The characteristics of calpain and proteasome systems in different molecular subtypes of breast cancer were studied. Tumor samples were obtained from 147 breast cancer patients, who were not previously treated with neoadjuvant therapy. Changes in the chymotrypsin-like proteasome activity and the correlation between proteasome and calpain activities were shown in different molecular subtypes of breast cancer. No changes in the calpain activity and proteasome subunits specific for various molecular subtypes of breast cancer were found. Our results show that the proteasome function undergoes changes depending on the receptor expression by tumor cells and this aspect should be further investigated.
About the Authors
E. E. Shashova
I.V. Kondakova1 Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk
Russian Federation
Russian Federation
MD, PhD, Senior Researcher, Laboratory of Tumor Biochemistry
5, Kooperativny str., 634009-Tomsk
SPIN-code: 5079-8784
A. V. Doroshenko
I.V. Kondakova1 Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk
Russian Federation
Russian Federation
MD, PhD, Researcher, General Oncology Department
5, Kooperativny str., 634009-Tomsk
SPIN-code: 7874-7606
L. N. Bondar
I.V. Kondakova1 Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk
Russian Federation
Russian Federation
MD, Physician, Department of Pathological Anatomy and Cytology
5, Kooperativny str., 634009-Tomsk
SPIN-code: 2620-1353
E. M. Slonimskaya
I.V. Kondakova1 Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk;
Siberian State Medical University, Russia, Tomsk
Russian Federation
Russian Federation
MD, DSс, Professor, Head of General Oncology Department
5, Kooperativny str., 634009-Tomsk
Professor of the Department of Oncology
2, Moskovskiy Tract, 634050-Tomsk
SPIN-code: 7763-6417
I. V. Kondakova
I.V. Kondakova1 Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk
Russian Federation
Russian Federation
MD, DSc, Head of Laboratory of Tumor Biochemistry
5, Kooperativny str., 634009-Tomsk
SPIN-code: 9338-4149
References
1. Sharova N.P. Role of proteasomes in cancer. Nature. 2008; 5: 20–26. [in Russian]
2. Grigoreva T.A., Tribulovich V.G., Garabadzhiu A.V., Melino G., Barlev N.A. The 26S proteasome is a multifaceted target for anti-cancer therapies. Oncotarget. 2015; 6 (28): 28. doi: 10.18632/oncotarget.4619.
3. Sorimachi H., Hata S., Ono Y. Calpain chronicle an enzyme family under multidisciplinary characterization. Proc Jpn Acad Ser B Phys Biol Sci. 2011; 87 (6): 287–327.
4. Storr S.J., Carragher N.O., Frame M.C., Parr T., Martin S.G. The calpain system and cancer. Nat Rev Cancer. 2011 May; 11 (5): 364–74. doi: 10.1038/nrc3050.
5. Spirina L.V., Kondakova I.V., Kolomiets L.А., Chernyshova A.L., Asadchikova О.N., Sharova N.P., Koval V.D. Proteasome activity and their subunit composition in endometrial hyperplasia and cancer. Tumors of female reproductive system. 2011; 4: 64–68. [in Russian]
6. Ivanova E.V., Kondakova I.V., Spirina L.V., Afanasyev S.G., Cheremisina О.V. Chimotrypsin-like proteasome activity and total activity of calpains in gastric and colon cancers. Newsletter of experimental biology and medicine. 2014; 157 (6): 753–756. [in Russian]
7. Shashova Е.Е., Astakhova Т.М., Plekhanova А.S., Bogomyagkova Yu.V., Lyupina Yu.V., Sumedi I.R., Slonimskaya Е.М., Erokhov P.А., Abramova Е.B., Rodoman G.V., Kuznetsov N.А., Kondakova I.V., Sharova N.P. Changes in chimotrypsin-like proteasome activity in the development of breast and thyroid carcinomas. Bull Exp Biol Med. 2013; 156 (8): 209–211. [in Russian]
8. Kakurina G.V., Kondakova I.V., Choinzonov E.L., Shishkin D.A., Cheremisina O.V. Assessment of blood serum proteome in patients with squamous cell head and neck carcinoma. Siberian Journal of Oncology. 2013. 2: 62–66. [in Russian]
9. Yunusova N.V., Spirina L.V., Kondakova I.V., Kolomiets L.А., Villert А.B., Shpilyeva О.V. Expression and activity of proteases in metastatic ovarian cancer. Proceedings of the Russian Academy of Sciences. The biological series. 2014; 5: 448–455. [in Russian]
10. Yurmazov Z.А., Spirina L.V., Usynin Е.А., Kondakova I.V., Slonimskaya Е.М. Molecular factors related to everolimus efficacy in patients with disseminated kidney cancer. Siberian Journal of Oncology. 2016; 15 (2): 42–47. doi:10.21294/1814-4861-2016-15-2-42-47. [in Russian]
11. Yurmazov Z.А., Spirina L.V., Usynin Е.А., Kondakova I.V., Slonimskaya Е.М. The effect of targeted therapy on the content of transcription and growth factors, mTOR proteinkinase and activity of intracellular proteinases in patients with disseminated kidney cancer. Bull Exp Biol Med. 2015; 160 (12): 768–772. [in Russian]
12. Shashova Е.Е., Kondakova I.V., Slonimskaya Е.М., Glushchenko S.A., Kolegova Е.S. Changes in chimotrypsin-like and caspase-like proteasome activity depending on the extent of breast cancer involvement. Siberian Journal of Oncology. 2013; 5: 45–49. [in Russian]
13. Storr S.J., Lee K.W., Woolston C.M., Safuan S., Green A.R., Macmillan R.D., Benhasouna A., Parr T., Ellis I.O., Martin S.G. Calpain system protein expression in basal-like and triple-negative invasive breast cancer. Ann Oncol. 2011; 23 (9): 2289–2296. doi: 10.1093/annonc/mds176.
14. Slonimskaya Е.М., Vtorushin S.V., Babyshkina N.N., Patalyak S.V. Role of morphological and genetic characteristics of estrogen receptor alpha in the development of resistance to endocrinotherapy with tamoxifen in patients with luminal breast cancer. Siberian Journal of Oncology. 2014; 3: 39–44. [in Russian]
15. Babyshkina N., Vtorushin S., Zavyalova M., Patalyak S., Dronova T., Litviakov N., Slonimskaya E., Kzhyshkowska J., Cherdyntseva N., Choynzonov E. The distribution pattern of ERa expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen. Clin Exp Med. 2016. doi 10.1007/s10238-016-0428-z.
16. Bonella F., Sixt S.U., Thomassen J., Schmidt M., Cai M., Mori T., Guzman J., Costabel U. Extracellular 20S proteasome in BAL and serum of patients with alveolar proteinosis. Immunobiology. 2015; 220 (3): 382–388. doi:10.1016/j.imbio.2014.10.010.
17. Ogawa S., Shih L.-Y., Suzuki T., Otsu M., Nakauchi H., Koeffler H.P., Sanada M. Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms. Clin Cancer Res. 2010; 16: 3825–31. doi: 10.1158/1078-0432.CCR-09-2341.
18. Powers G.L., Ellison-Zelski S.J., Casa A.J. Proteasome inhibition represses ER gene expression in ER+ cells – a new link between proteasome activity and rstrogen signaling in breast cancer. Oncogene. 2010; 29: 1509–1518. doi: 10.1038/onc.2009.434.
19. Spirina L.V., Kondakova I.V., Choynzonov E.L., Chigevskaya S.Y., Shishkin D.A., Kulbakin D.Y. Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-KB expression in squamous cell carcinoma of head and nesk; association with proteasome and calpain activities. J Cancer Res Clin Oncol. 2013; 139 (4): 625–633. doi: 10.1007/ s00432-012-1366-0. doi: 10.1007/s00432-012-1366-0
20. Shashova E., Lyupina Yu.V., Glushchenko S.A., Slonimskaya E.M., Savenkova O.V., Kulikov A.M., Gornostaev N.G., Kondakova I.V., Sharova N.P. Proteasome functioning in breast cancer: connection with clinicalpathological factors. PLOS ONE. 2014; 9 (10): e109933. http://dx.doi. org/10.1371/journal.pone.0109933.
21. Ben-Shahar S., Komlosh A., Nadav E., Shaked I., Ziv T., Admon A., DeMartino G.N., Reiss Y. 26 S proteasome-mediated production of an authentic major histocompatibility class I-restricted epitope from an intact protein substrate. J Biol Chem. 1999; 274 (31): 21963–21972.
22. Sandmann S., Prenzel F., Shaw L., Schauer R., Unger T. Activity profile of calpains I and II in chronically infarcted rat myocardiuminfluence of the calpain inhibitor CAL 9961. Br J Pharmacol. 2002; 135 (8): 1951–1958.
Review
For citations:
Shashova E.E., Doroshenko A.V., Bondar L.N., Slonimskaya E.M., Kondakova I.V. PROTEASOMAL AND CALPAIN PROTEOLYSIS SYSTEMS IN DIFFERENT MOLECULAR SUBTYPES OF BREAST CANCER. Siberian journal of oncology. 2017;16(3):33-39. (In Russ.) https://doi.org/10.21294/1814-4861-2017-16-3-33-39
Views:
878
Email this article 
